- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)
- These three simultaneous approvals conducted under FDA Priority Review follow Breakthrough Therapy Designations to address the unmet need of patients
- Ilaris provides rapid and sustained disease control for patients with these rare and debilitating Periodic Fever Syndromes
EAST HANOVER, N.J., Sept. 23, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.
Ilaris is the first and only FDA-approved biologic treatment for patients with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF).1,2 All three conditions are part of a group of rare autoinflammatory diseases called Periodic Fever Syndromes, which are also referred to as Hereditary Periodic Fevers (HPF). The most common syndrome is FMF, which mainly affects people of Eastern Mediterranean ancestry. It affects 1 in 250 to 1 in 1,000 individuals in these populations, many of whom are children.3
"We are grateful to the scientists, clinical trial investigators and all associates who worked tirelessly in support of patients to gain three simultaneous FDA approvals of ILARIS," said Fabrice Chouraqui, President of Novartis Pharmaceuticals Corporation, "It is through their hard work that Novartis can offer a desperately needed new treatment option to the adults and children who suffer from these debilitating conditions and continue to serve the rare disease community."
The FDA approvals are based on results from the pivotal Phase III CLUSTER study which showed rapid (at Day 15) and sustained disease control with Ilaris compared to placebo through 16 weeks, in patients with either TRAPS, HIDS/MKD or FMF.2 As a result of the positive data, the FDA granted Ilaris Breakthrough Therapy status and priority reviews for each of the three Periodic Fever Syndrome conditions.
Periodic Fever Syndromes are a group of rare autoinflammatory diseases that cause disabling and persistent fevers which may be accompanied by joint pain, swelling, muscle pain and skin rashes with complications that can be life-threatening.1
"Adults and children living with TRAPS, HIDS/MKD or FMF often experience extensive delays in diagnosis because the disorders are so rare that many physicians are unaware of them," said Hal M. Hoffman, M.D., chief of Pediatric Allergy, Immunology, and Rheumatology at Rady Children's Hospital-San Diego and University of California San Diego. "Following diagnosis, our goal is to get patients treated as soon as possible and that has been challenging due to the lack of available treatment options. That's what makes these three approvals for ILARIS so important for patients."
Ilaris is already approved and marketed in the US as an effective and well-tolerated treatment for another Periodic Fever Syndrome condition – Cryopyrin-Associated Periodic Syndromes (CAPS), and another autoinflammatory condition – Systemic Juvenile Idiopathic Arthritis (SJIA).
About Periodic Fever Syndromes
Periodic Fever Syndromes are a group of diseases that cause serious recurrent fever and inflammation through non-infectious activation of the immune system. Most patients present with symptoms in infancy or childhood, but in some patients the condition only becomes apparent or diagnosed in adulthood.1
Previous treatments for these rare conditions consisted of oral anti-inflammatory drugs, such as corticosteroids, which were used only to help manage the symptoms. While other medicines, such as non-steroidal anti-inflammatory drugs, have also been used to help reduce symptoms, they do not prevent or change the overall course of a flare.1
About Ilaris
Ilaris is a selective, high-affinity, human monoclonal antibody that inhibits Interleukin-1 (IL-1) beta, which is an important part of the body's immune system defenses.4 Excessive production of IL-1 beta plays a prominent role in certain inflammatory diseases.5,6 Ilaris works by blocking the action of IL-1 beta for a sustained period of time, therefore inhibiting inflammation that is caused by its over-production.4
Ilaris is currently approved and marketed for the treatment of SJIA in the US and EU and for the treatment of Adult-Onset Still's Disease (AOSD) and the symptomatic treatment of refractory acute gouty arthritis in the EU. Ilaris is also approved in more than 70 countries, including in the EU, Switzerland, Canada, and Japan for the treatment of the Periodic Fever Syndrome CAPS: rare, lifelong, genetic disorders with debilitating symptoms. In the US, Ilaris is approved for two subtypes of CAPS: Muckle-Wells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS). The approved indications may vary depending upon the individual country.
- These three simultaneous approvals conducted under FDA Priority Review follow Breakthrough Therapy Designations to address the unmet need of patients
- Ilaris provides rapid and sustained disease control for patients with these rare and debilitating Periodic Fever Syndromes
EAST HANOVER, N.J., Sept. 23, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.
Ilaris is the first and only FDA-approved biologic treatment for patients with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF).1,2 All three conditions are part of a group of rare autoinflammatory diseases called Periodic Fever Syndromes, which are also referred to as Hereditary Periodic Fevers (HPF). The most common syndrome is FMF, which mainly affects people of Eastern Mediterranean ancestry. It affects 1 in 250 to 1 in 1,000 individuals in these populations, many of whom are children.3
"We are grateful to the scientists, clinical trial investigators and all associates who worked tirelessly in support of patients to gain three simultaneous FDA approvals of ILARIS," said Fabrice Chouraqui, President of Novartis Pharmaceuticals Corporation, "It is through their hard work that Novartis can offer a desperately needed new treatment option to the adults and children who suffer from these debilitating conditions and continue to serve the rare disease community."
The FDA approvals are based on results from the pivotal Phase III CLUSTER study which showed rapid (at Day 15) and sustained disease control with Ilaris compared to placebo through 16 weeks, in patients with either TRAPS, HIDS/MKD or FMF.2 As a result of the positive data, the FDA granted Ilaris Breakthrough Therapy status and priority reviews for each of the three Periodic Fever Syndrome conditions.
Periodic Fever Syndromes are a group of rare autoinflammatory diseases that cause disabling and persistent fevers which may be accompanied by joint pain, swelling, muscle pain and skin rashes with complications that can be life-threatening.1
"Adults and children living with TRAPS, HIDS/MKD or FMF often experience extensive delays in diagnosis because the disorders are so rare that many physicians are unaware of them," said Hal M. Hoffman, M.D., chief of Pediatric Allergy, Immunology, and Rheumatology at Rady Children's Hospital-San Diego and University of California San Diego. "Following diagnosis, our goal is to get patients treated as soon as possible and that has been challenging due to the lack of available treatment options. That's what makes these three approvals for ILARIS so important for patients."
Ilaris is already approved and marketed in the US as an effective and well-tolerated treatment for another Periodic Fever Syndrome condition – Cryopyrin-Associated Periodic Syndromes (CAPS), and another autoinflammatory condition – Systemic Juvenile Idiopathic Arthritis (SJIA).
About Periodic Fever Syndromes
Periodic Fever Syndromes are a group of diseases that cause serious recurrent fever and inflammation through non-infectious activation of the immune system. Most patients present with symptoms in infancy or childhood, but in some patients the condition only becomes apparent or diagnosed in adulthood.1
Previous treatments for these rare conditions consisted of oral anti-inflammatory drugs, such as corticosteroids, which were used only to help manage the symptoms. While other medicines, such as non-steroidal anti-inflammatory drugs, have also been used to help reduce symptoms, they do not prevent or change the overall course of a flare.1
About Ilaris
Ilaris is a selective, high-affinity, human monoclonal antibody that inhibits Interleukin-1 (IL-1) beta, which is an important part of the body's immune system defenses.4 Excessive production of IL-1 beta plays a prominent role in certain inflammatory diseases.5,6 Ilaris works by blocking the action of IL-1 beta for a sustained period of time, therefore inhibiting inflammation that is caused by its over-production.4
Ilaris is currently approved and marketed for the treatment of SJIA in the US and EU and for the treatment of Adult-Onset Still's Disease (AOSD) and the symptomatic treatment of refractory acute gouty arthritis in the EU. Ilaris is also approved in more than 70 countries, including in the EU, Switzerland, Canada, and Japan for the treatment of the Periodic Fever Syndrome CAPS: rare, lifelong, genetic disorders with debilitating symptoms. In the US, Ilaris is approved for two subtypes of CAPS: Muckle-Wells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS). The approved indications may vary depending upon the individual country.